Emilija Nestorovic1, Jan D Schmitto2, Sudhir S Kushwaha3, Svetozar Putnik1, Dusko Terzic1, Natasa Milic4,5, Aleksandar Mikic1, Dejan Markovic6, Danijela Trifunovic7, Arsen Ristic7, Miljko Ristic1. 1. Department for Heart Transplant, LVAD and ECMO, Hospital for Cardiac Surgery, Clinical Center of Serbia, Belgrade, Serbia. 2. Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany. 3. Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA. 4. Department for Medical Statistics and Informatics, Medical Faculty University of Belgrade, Belgrade, Serbia. 5. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA. 6. Center for Anesthesiology and Resuscitation, Clinical Center of Serbia, Belgrade, Serbia. 7. Cardiology Clinic, Clinical Center of Serbia, Belgrade, Serbia.
Abstract
BACKGROUND: The primary goal of this study was to evaluate the outcomes of patients with end-stage heart failure (HF) who underwent continuous flow left ventricular assist device (CF-LVAD) in a developing country and to compare to those reported by more developed countries. The secondary goal was on determining factors that may be connected to improved survival. METHODS: We prospectively analyzed 47 consecutive patients who underwent CF-LVAD at our institution. After one year the survival and adverse event profiles of patients were evaluated. At 3, 6 and 12 months, the cardiac, renal and liver function outcomes were assessed. RESULTS: The 30-day, 6-month and 1-year survival rates were 89%, 85% and 80%, respectively. A significant improvement in dimensions and ejection fraction of left ventricle, BNP, functional capacity, blood urea nitrogen (BUN) and total bilirubin (P<0.05 for all) were noticed 3 months post-CF-LVAD implantation, and patients were stable throughout the entire first year follow up. In the group of patients with baseline renal dysfunction (RD) there were significant improvements of renal function (P=0.004), with no changes on follow up. 57% of patients exhibited some kind of adverse event, commonly in the form of bleeding. In multivariate Cox regression analysis renal failure was found to be as an independent risk factor for the overall survival (HR =13.1, P<0.001). CONCLUSIONS: In conclusion, our data extends previous findings from centers of developed countries, that CF-LVAD is an adequate treatment option for patients suffering from end-stage HF, and encourages expansion of CF-LVAD implantation in developing countries with nascent HT program.
BACKGROUND: The primary goal of this study was to evaluate the outcomes of patients with end-stage heart failure (HF) who underwent continuous flow left ventricular assist device (CF-LVAD) in a developing country and to compare to those reported by more developed countries. The secondary goal was on determining factors that may be connected to improved survival. METHODS: We prospectively analyzed 47 consecutive patients who underwent CF-LVAD at our institution. After one year the survival and adverse event profiles of patients were evaluated. At 3, 6 and 12 months, the cardiac, renal and liver function outcomes were assessed. RESULTS: The 30-day, 6-month and 1-year survival rates were 89%, 85% and 80%, respectively. A significant improvement in dimensions and ejection fraction of left ventricle, BNP, functional capacity, blood urea nitrogen (BUN) and total bilirubin (P<0.05 for all) were noticed 3 months post-CF-LVAD implantation, and patients were stable throughout the entire first year follow up. In the group of patients with baseline renal dysfunction (RD) there were significant improvements of renal function (P=0.004), with no changes on follow up. 57% of patients exhibited some kind of adverse event, commonly in the form of bleeding. In multivariate Cox regression analysis renal failure was found to be as an independent risk factor for the overall survival (HR =13.1, P<0.001). CONCLUSIONS: In conclusion, our data extends previous findings from centers of developed countries, that CF-LVAD is an adequate treatment option for patients suffering from end-stage HF, and encourages expansion of CF-LVAD implantation in developing countries with nascent HT program.
Entities:
Keywords:
Left ventricular assist device (LVAD); end-stage heart failure; less developed country; outcomes
Authors: Soon J Park; Carmelo A Milano; Antone J Tatooles; Joseph G Rogers; Robert M Adamson; D Eric Steidley; Gregory A Ewald; Kartik S Sundareswaran; David J Farrar; Mark S Slaughter Journal: Circ Heart Fail Date: 2012-01-26 Impact factor: 8.790
Authors: Stuart D Russell; Joseph G Rogers; Carmelo A Milano; David B Dyke; Francis D Pagani; Juan M Aranda; Charles T Klodell; Andrew J Boyle; Ranjit John; Leway Chen; H Todd Massey; David J Farrar; John V Conte Journal: Circulation Date: 2009-11-23 Impact factor: 29.690
Authors: Jan D Schmitto; Jasmin S Hanke; Sebastian V Rojas; Murat Avsar; Axel Haverich Journal: J Heart Lung Transplant Date: 2015-03-07 Impact factor: 10.247
Authors: Jeffrey A Morgan; Pauline H Go; Linnea Xuereb; Babbaljeet Kaur; Silvy Akrawe; Hassan W Nemeh; Jamil Borgi; David E Lanfear; Celeste T Williams; Gaetano Paone Journal: Ann Thorac Surg Date: 2016-05-10 Impact factor: 4.330
Authors: Leslie W Miller; Francis D Pagani; Stuart D Russell; Ranjit John; Andrew J Boyle; Keith D Aaronson; John V Conte; Yoshifumi Naka; Donna Mancini; Reynolds M Delgado; Thomas E MacGillivray; David J Farrar; O H Frazier Journal: N Engl J Med Date: 2007-08-30 Impact factor: 91.245
Authors: Mark S Slaughter; Joseph G Rogers; Carmelo A Milano; Stuart D Russell; John V Conte; David Feldman; Benjamin Sun; Antone J Tatooles; Reynolds M Delgado; James W Long; Thomas C Wozniak; Waqas Ghumman; David J Farrar; O Howard Frazier Journal: N Engl J Med Date: 2009-11-17 Impact factor: 91.245
Authors: Sigrid E Sandner; Daniel Zimpfer; Philipp Zrunek; Angela Rajek; Heinrich Schima; Daniela Dunkler; Michael Grimm; Ernst Wolner; Georg M Wieselthaler Journal: Ann Thorac Surg Date: 2009-04 Impact factor: 4.330
Authors: Sigrid E Sandner; Daniel Zimpfer; Philipp Zrunek; Angela Rajek; Heinrich Schima; Daniela Dunkler; Andreas O Zuckermann; Georg M Wieselthaler Journal: J Heart Lung Transplant Date: 2009-04 Impact factor: 10.247
Authors: Thibault Schaeffer; Otmar Pfister; Constantin Mork; Paul Mohacsi; Florian Rueter; Simon Scheifele; Anne Morgen; Urs Zenklusen; Thomas Doebele; Markus Maurer; Joachim Erb; Jens Fassl; Nadine Cueni; Martin Siegemund; Hans Pargger; Brigitta Gahl; Stefan Osswald; Friedrich Eckstein; Martin Grapow Journal: J Cardiothorac Surg Date: 2021-03-31 Impact factor: 1.637